1. Home
  2. MDWD vs SLND Comparison

MDWD vs SLND Comparison

Compare MDWD & SLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • SLND
  • Stock Information
  • Founded
  • MDWD 2000
  • SLND 1900
  • Country
  • MDWD Israel
  • SLND United States
  • Employees
  • MDWD N/A
  • SLND N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • SLND Military/Government/Technical
  • Sector
  • MDWD Health Care
  • SLND Industrials
  • Exchange
  • MDWD Nasdaq
  • SLND Nasdaq
  • Market Cap
  • MDWD 195.2M
  • SLND 210.6M
  • IPO Year
  • MDWD 2014
  • SLND N/A
  • Fundamental
  • Price
  • MDWD $19.47
  • SLND $4.43
  • Analyst Decision
  • MDWD Strong Buy
  • SLND Buy
  • Analyst Count
  • MDWD 2
  • SLND 2
  • Target Price
  • MDWD $35.00
  • SLND $4.50
  • AVG Volume (30 Days)
  • MDWD 83.0K
  • SLND 121.0K
  • Earning Date
  • MDWD 11-25-2025
  • SLND 11-11-2025
  • Dividend Yield
  • MDWD N/A
  • SLND N/A
  • EPS Growth
  • MDWD N/A
  • SLND N/A
  • EPS
  • MDWD N/A
  • SLND N/A
  • Revenue
  • MDWD $19,858,000.00
  • SLND $895,438,000.00
  • Revenue This Year
  • MDWD $21.39
  • SLND N/A
  • Revenue Next Year
  • MDWD $23.01
  • SLND $3.50
  • P/E Ratio
  • MDWD N/A
  • SLND N/A
  • Revenue Growth
  • MDWD N/A
  • SLND N/A
  • 52 Week Low
  • MDWD $14.14
  • SLND $1.85
  • 52 Week High
  • MDWD $22.51
  • SLND $4.90
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 66.30
  • SLND 50.85
  • Support Level
  • MDWD $17.72
  • SLND $4.23
  • Resistance Level
  • MDWD $18.54
  • SLND $4.66
  • Average True Range (ATR)
  • MDWD 0.62
  • SLND 0.28
  • MACD
  • MDWD 0.22
  • SLND -0.01
  • Stochastic Oscillator
  • MDWD 86.01
  • SLND 50.00

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About SLND Southland Holdings Inc.

Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures. The company operates in two distinct segments: Civil and Transportation. The civil segment operates throughout North America and specializes in services that include the design and construction of water pipelines, pump stations, lift stations, water and wastewater treatment plants, concrete and structural steel, outfall, and tunneling. The transportation segment operates throughout North America and specializes in services that include the design and construction of bridges, roadways, marine, dredging, ship terminals and piers, and specialty structures and facilities.

Share on Social Networks: